KYMR
Kymera Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+10/100
Last price
104.18
▼ 5.67 (5.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
109.85
Prev close
109.85
Day high
111.04
Day low
101.75
Volume
960.69K
Market cap
$8.72B
P/E (TTM)
—
52W range
55.26 – 130.05
Day trading desk
Gap from prior close
+0.00%
Prior close 109.85
VWAP
105.04
-0.82% from price
Relative volume
1.12×
Normal
Session range
9.98%
101.75 – 111.90
Position in range
24%
Near session low
ATR (14D)
5.51
5.29% of price
Prior day high
109.92
PDH
Prior day low
103.33
PDL
Bid / ask spread
—
Quote not published
Session volume
773.48K
Avg 688.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.10%
-6.0%
1M
-9.72%
-10.9%
3M
-7.17%
-11.7%
6M
+24.54%
+6.4%
YTD
+36.20%
+22.0%
1Y
+83.04%
+66.6%
3Y
+662.45%
+580.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KYMR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-1.62M
Net selling
Buy transactions
15
337.88K shares
Sell transactions
16
1.95M shares
Net transactions
+31
Buys less sells
Sell : buy shares
5.8 : 1
Heavily one-sided
Insider-held shares
1.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | MAINOLFI NELLO Chief Executive Officer |
CONVERSION | 30.00K | $62.40K | Direct |
| Oct 1, 26 | MAINOLFI NELLO Chief Executive Officer |
SELL | 30.00K | $3.41M | Direct |
| Sep 4, 26 | ADAMS BRIAN R Officer |
SELL | 6.37K | $744.30K | Direct |
| Jul 27, 26 | ROONEY TERENCE Officer |
STOCK | 38.00K | $0 | Direct |
| Jul 7, 26 | MAINOLFI NELLO Chief Executive Officer |
CONVERSION | 50.00K | $104.00K | Direct |
| Jul 7, 26 | MAINOLFI NELLO Chief Executive Officer |
SELL | 50.00K | $5.95M | Direct |
| Jul 1, 26 | MAINOLFI NELLO Chief Executive Officer |
CONVERSION | 80.00K | $166.40K | Direct |
| Jul 1, 26 | MAINOLFI NELLO Chief Executive Officer |
SELL | 80.00K | $9.22M | Direct |
| Jul 1, 26 | GOODMAN NOAH Officer |
SELL | 3.39K | $387.33K | Direct |
| Jun 30, 26 | JACOBS BRUCE N. Chief Financial Officer |
CONVERSION | 61.38K | $327.14K | Direct |
| Jun 30, 26 | JACOBS BRUCE N. Chief Financial Officer |
SELL | 77.11K | $8.86M | Direct |
| Jun 26, 26 | BVF PARTNERS L.P. Affiliated Person |
SELL | 1.63M | $173.67M | Indirect |
| Jun 25, 26 | GOODMAN NOAH Officer |
CONVERSION | 5.00K | $105.25K | Direct |
| Jun 25, 26 | GOODMAN NOAH Officer |
SELL | 5.00K | $570.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS BRIAN R |
Officer | 50.25K | Sale |
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BVF PARTNERS L P |
Affiliated Person | — | Purchase |
BVF PARTNERS L.P. |
Affiliated Person | — | Sale |
CHADWICK JEREMY G |
Chief Operating Officer | 44.02K | Sale |
CHINIARA ELLEN V |
Officer | 80.08K | Sale |
GOLLOB JARED AUGUST |
Officer | 117.13K | Sale |
GOODMAN NOAH |
Officer | 47.18K | Sale |
JACOBS BRUCE N. |
Chief Financial Officer | 244.88K | Conversion of Exercise of derivative security |
MAINOLFI NELLO |
Chief Executive Officer | 666.57K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$8.72B
Enterprise value$8.20B
Revenue (TTM)$105.00M
Gross profit$-270.57M
EBITDA$-339.89M
Net income$-299.60M
EPS (TTM)$-3.13
Free cash flow$-144.07M
Total cash$690.99M
Total debt$78.56M
Book value / share$18.23
Shares outstanding82.26M
Float66.04M
Short % of float16.29%
Dividend yield0.00%
Beta (5Y)1.98
Valuation & profitability ratios
Trailing P/E—
Forward P/E-20.84
PEG ratio—
Price / sales—
Price / book5.81
EV / revenue78.09
EV / EBITDA-24.13
Gross margin-257.69%
Operating margin-116.32%
Profit margin-285.33%
Return on equity-24.15%
Return on assets-15.59%
Debt / equity5.21
Current ratio10.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $39.21M | $47.07M | $78.59M | $46.83M | -16.7% |
| Operating revenue | $39.21M | $47.07M | $78.59M | $46.83M | -16.7% |
| Research & development | $316.57M | $240.25M | $189.08M | $164.25M | +31.8% |
| Selling, general & admin | $68.19M | $63.53M | $55.04M | $43.83M | +7.3% |
| Total operating expense | $384.75M | $303.78M | $244.12M | $208.08M | +26.7% |
| Operating income | -$345.54M | -$256.71M | -$165.53M | -$161.26M | -34.6% |
| Net interest income | $38.05M | $37.78M | $18.57M | $6.45M | +0.7% |
| Pre-tax income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -39.1% |
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -39.1% |
| Net income to common | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -39.1% |
| Basic EPS | -3.69 | -2.98 | -2.52 | -2.87 | -23.8% |
| Diluted EPS | -3.69 | -2.98 | -2.52 | -2.87 | -23.8% |
| EBIT | -$310.98M | -$223.61M | -$146.77M | -$154.63M | -39.1% |
| EBITDA | -$302.67M | -$216.24M | -$143.20M | -$151.66M | -40.0% |
| Basic shares | 84.49M | 75.04M | 58.37M | 53.93M | +12.6% |
| Diluted shares | 84.49M | 75.04M | 58.37M | 53.93M | +12.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $357.01M | $120.26M | $109.97M | $68.39M | — | +196.9% |
| Cash & short-term investments | $848.28M | $488.74M | $374.88M | $407.17M | — | +73.6% |
| Accounts receivable | — | $0 | $15.00M | $0 | $0 | — |
| Total current assets | $871.21M | $510.27M | $405.32M | $419.42M | — | +70.7% |
| Property, plant & equipment | $85.53M | $97.86M | $101.08M | $22.24M | — | -12.6% |
| Total assets | $1.74B | $978.03M | $575.76M | $603.13M | — | +78.2% |
| Total current liabilities | $83.21M | $67.77M | $85.69M | $71.34M | — | +22.8% |
| Total debt | $82.25M | $87.76M | $84.67M | $17.34M | — | -6.3% |
| Total liabilities | $163.15M | $142.42M | $180.79M | $112.98M | — | +14.6% |
| Retained earnings | -$1.07B | -$754.61M | -$530.75M | -$383.79M | — | -41.3% |
| Shareholder equity | $1.58B | $835.62M | $394.97M | $490.15M | — | +89.0% |
| Working capital | $788.00M | $442.50M | $319.63M | $348.07M | — | +78.1% |
| Net tangible assets | $1.58B | $835.62M | $394.97M | $490.15M | — | +89.0% |
| Shares issued | 81.32M | 64.89M | 55.59M | 55.04M | — | +25.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -39.1% |
| Depreciation & amortisation | $8.31M | $7.37M | $3.56M | $2.98M | +12.7% |
| Stock-based compensation | $59.90M | $55.01M | $43.12M | $35.48M | +8.9% |
| Change in working capital | $15.27M | -$23.97M | $2.68M | -$37.62M | +163.7% |
| Operating cash flow | -$232.89M | -$194.50M | -$102.83M | -$153.09M | -19.7% |
| Capital expenditure | -$1.45M | -$12.84M | -$34.48M | -$2.84M | +88.7% |
| Investing cash flow | -$521.06M | -$404.08M | $139.89M | $20.52M | -29.0% |
| Financing cash flow | $990.71M | $608.85M | $4.19M | $153.00M | +62.7% |
| Free cash flow | -$234.34M | -$207.34M | -$137.31M | -$155.92M | -13.0% |
| End cash position | $362.81M | $126.05M | $115.78M | $74.53M | +187.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $65.00M | $34.37M | $2.87M | $2.76M | $11.48M | +89.1% |
| Operating revenue | $65.00M | $34.37M | $2.87M | $2.76M | $11.48M | +89.1% |
| Research & development | $119.48M | $98.16M | $83.83M | $74.09M | $78.39M | +21.7% |
| Selling, general & admin | $21.13M | $20.36M | $16.93M | $17.34M | $17.64M | +3.8% |
| Total operating expense | $140.61M | $118.52M | $100.77M | $91.43M | $96.03M | +18.6% |
| Operating income | -$75.61M | -$84.15M | -$97.90M | -$88.67M | -$84.56M | +10.2% |
| Net interest income | $14.40M | $14.92M | $10.91M | $10.35M | $7.94M | -3.5% |
| Pre-tax income | -$61.21M | -$69.23M | -$86.98M | -$82.17M | -$76.61M | +11.6% |
| Net income | -$61.21M | -$69.23M | -$86.98M | -$82.17M | -$76.61M | +11.6% |
| Net income to common | -$61.21M | -$69.23M | -$86.98M | -$82.17M | -$76.61M | +11.6% |
| Basic EPS | -0.62 | -0.71 | -0.97 | -0.94 | -0.95 | +12.7% |
| Diluted EPS | -0.62 | -0.71 | -0.97 | -0.94 | -0.95 | +12.7% |
| EBIT | -$61.13M | -$69.17M | -$86.89M | -$82.08M | -$76.51M | +11.6% |
| EBITDA | -$59.10M | -$67.15M | -$84.86M | -$79.93M | -$74.42M | +12.0% |
| Basic shares | 98.18M | 97.53M | 89.91M | 87.30M | 80.45M | +0.7% |
| Diluted shares | 98.18M | 97.53M | 89.91M | 87.30M | 80.45M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $124.48M | $144.09M | $357.01M | $112.95M | $335.82M | -13.6% |
| Cash & short-term investments | $690.99M | $650.93M | $848.28M | $505.68M | $665.45M | +6.2% |
| Accounts receivable | $20.00M | — | — | — | $40.00M | — |
| Total current assets | $737.26M | $677.43M | $871.21M | $528.30M | $728.33M | +8.8% |
| Property, plant & equipment | $81.07M | $83.35M | $85.53M | $88.08M | $94.62M | -2.7% |
| Total assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | -1.4% |
| Total current liabilities | $71.33M | $62.64M | $83.21M | $71.58M | $87.54M | +13.9% |
| Total debt | $78.56M | $80.47M | $82.25M | $84.00M | $85.71M | -2.4% |
| Total liabilities | $136.19M | $129.38M | $163.15M | $155.79M | $159.59M | +5.3% |
| Retained earnings | -$1.20B | -$1.14B | -$1.07B | -$978.98M | -$896.80M | -5.4% |
| Shareholder equity | $1.51B | $1.54B | $1.58B | $946.26M | $971.48M | -2.0% |
| Working capital | $665.94M | $614.79M | $788.00M | $456.72M | $640.79M | +8.3% |
| Net tangible assets | $1.51B | $1.54B | $1.58B | $946.26M | $971.48M | -2.0% |
| Shares issued | 82.79M | 82.18M | 81.32M | 71.74M | 70.16M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$61.21M | -$69.23M | -$86.98M | -$82.17M | -$76.61M | +11.6% |
| Depreciation & amortisation | $2.03M | $2.02M | $2.03M | $2.15M | $2.08M | +0.4% |
| Stock-based compensation | $18.94M | $16.01M | $14.45M | $15.80M | $15.42M | +18.3% |
| Change in working capital | -$11.49M | -$34.91M | $5.79M | $35.45M | $1.35M | +67.1% |
| Operating cash flow | -$54.06M | -$88.84M | -$66.75M | -$27.11M | -$59.88M | +39.1% |
| Capital expenditure | -$473.00K | -$434.00K | -$106.00K | -$181.00K | -$695.00K | -9.0% |
| Investing cash flow | $20.05M | -$142.84M | -$394.40M | -$235.30M | $60.02M | +114.0% |
| Financing cash flow | $14.42M | $18.77M | $705.22M | $39.51M | $245.73M | -23.2% |
| Free cash flow | -$54.54M | -$89.27M | -$66.85M | -$27.29M | -$60.58M | +38.9% |
| End cash position | $130.30M | $149.90M | $362.81M | $118.74M | $341.64M | -13.1% |
Options analytics
Put / call volume
0.10
Call-heavy session
Put / call open interest
0.54
Positioning, not flow
Max pain
110.00
+3.8% from spot
ATM implied vol
65.4%
Nearest strike to spot
Skew (10% OTM)
+1.5%
Puts bid over calls
Call volume
39
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
120.00
8 contracts
Heaviest put OI
105.00
8 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.74 | -0.62 | +16.0% |
| Mar 2026 | -0.86 | -0.71 | +17.1% |
| Dec 2025 | -0.77 | -0.98 | -27.1% |
| Sep 2025 | -0.78 | -0.94 | -20.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.26 | 20 | $3.10M | +12.3% |
| Next quarter | -1.25 | 20 | $3.50M | +22.0% |
| Current year | -3.84 | 20 | $105.03M | +167.9% |
| Next year | -5.09 | 20 | $40.21M | -61.7% |
Analyst targets & ownership
Mean target$139.32
High target$180.00
Low target$111.00
Implied upside33.73%
Analyst count22
ConsensusSTRONG BUY
Strong buy / Buy4 / 17
Hold2
Sell / Strong sell0 / 0
Held by insiders2.12%
Held by institutions119.36%
Institutions holding397
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
111.09
-6.22% from price
SMA 20
113.92
-6.97% from price
SMA 50
114.38
-7.34% from price
SMA 100
105.25
-1.01% from price
SMA 200
93.28
+13.62% from price
EMA 12
111.35
-6.44% from price
EMA 26
113.46
-8.18% from price
EMA 50
112.60
-7.48% from price
RSI (14)
36.6
Neutral
MACD (12,26,9)
-2.11
Hist -1.07
ATR (14)
5.51
5.20% of price
Realised vol 30D
34.8%
Annualised
Bollinger upper
121.69
20, 2σ
Bollinger lower
106.15
20, 2σ
50 / 200 cross
Golden
114.38 vs 93.28
Trend bias
Above 200
+13.62%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.79
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
34.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.7%
Peak to trough
Max drawdown 5Y
-83.3%
Peak to trough
ATR 14
5.51
5.20% of price
Beta (reported)
1.98
5Y monthly, from filing
Short interest
Shares short
10.53M
Prior 10.38M
Change vs prior
+1.4%
Shorts adding
% of float
16.29%
Elevated
% of shares out
12.66%
Against total outstanding
Days to cover
16.4
Crowded exit
Float
66.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Sep 22, 26 | Stifel | MAINTAINED | Buy | Buy |
| Sep 14, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Sep 10, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Aug 31, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 30, 26 | Deutsche Bank | INITIATED | — | Hold |
| Jul 28, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Jun 30, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-27
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-04-30
Proxy Statements
DEFA14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-03-27
Headlines
BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123
MT Newswires · 23d ago
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Zacks · 33d ago
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · 34d ago
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · 34d ago
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
MT Newswires · 35d ago
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
GlobeNewswire · 36d ago
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Motley Fool · 55d ago
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
MT Newswires · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.